Literature DB >> 7923008

Cellular DNA content and survival in advanced ovarian carcinoma.

J Pfisterer1, F Kommoss, W Sauerbrei, H Renz, A du Bois, M Kiechle-Schwarz, A Pfleiderer.   

Abstract

BACKGROUND: The prognosis of patients with advanced ovarian cancer is generally poor. To date, no satisfactory methods for predicting individual prognosis have been reported, especially in patients with little or no residual tumor after debulking.
METHODS: The authors investigated in a retrospective study the prognostic significance of nuclear DNA content as measured by flow cytometry of the tumor specimens from 184 women with nonpretreated International Federation of Gynecology and Obstetrics Stage III and IV ovarian cancer. Clearly defined inclusion criteria for the study population were used.
RESULTS: Seventy-one (39%) cancers were diploid, whereas 113 (61%) were aneuploid. Ploidy showed a significant correlation with clinical and morphologic features such as age, histologic grade, serous histologic type, and residual tumor after debulking. No significant correlation was found between ploidy and ascites, estrogen- and progesterone receptor levels, and elevated pretreatment CA-125 levels. Univariate analysis showed significant correlations between overall survival and histologic grade (P = 0.003), patient age (P = 0.001), residual tumor after primary surgery (P < 0.001), stage (P = 0.019) and ploidy (P = 0.009). Multivariate analysis revealed residual tumor (P < 0.001) and age (P = 0.051) to be associated independently with survival. Ploidy was not established as an independent prognostic factor.
CONCLUSIONS: These results suggest that abnormalities of the nuclear DNA content in advanced ovarian carcinomas are associated with various clinical and morphologic prognosticators, but that ploidy is not an independent prognostic factor for survival.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923008     DOI: 10.1002/1097-0142(19941101)74:9<2509::aid-cncr2820740919>3.0.co;2-f

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  BMC Med       Date:  2012-05-29       Impact factor: 8.775

2.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

3.  Error-promoting DNA synthesis in ovarian cancer cells.

Authors:  Heqiao Dai; Robert J Hickey; Jianying Liu; Robert M Bigsby; Carita Lanner; Linda H Malkas
Journal:  Gynecol Oncol       Date:  2013-07-12       Impact factor: 5.482

4.  DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer.

Authors:  Alain G Zeimet; Heidi Fiegl; Georg Goebel; Francis Kopp; Claude Allasia; Daniel Reimer; Ilona Steppan; Elisabeth Mueller-Holzner; Melanie Ehrlich; Christian Marth
Journal:  Gynecol Oncol       Date:  2011-01-20       Impact factor: 5.482

Review 5.  Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines.

Authors:  S Mallett; A Timmer; W Sauerbrei; D G Altman
Journal:  Br J Cancer       Date:  2009-12-08       Impact factor: 7.640

6.  DNA Cytometry and Nuclear Morphometry in Ovarian Benign, Borderline and Malignant Tumors.

Authors:  Amina A Gamal El Din; Manal A Badawi; Shereen E Abdel Aal; Nihad A Ibrahim; Fatma A Morsy; Nermeen M Shaffie
Journal:  Open Access Maced J Med Sci       Date:  2015-10-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.